Resumen de The role of Fibroblast Growth Factor 23 in chronic kidney disease-mineral and bone disorder
Fibroblast Growth Factor 23 (FGF-23) is a bone-derived hormone involved in the regulation of phosphate ho - meostasis. FGF-23 levels are extremely elevated in Chron - ic Kidney Disease (CKD) and there is evidence supporting the role of this hormone in the pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Furthermore, recent data associates FGF-23 with the pathogenesis of systemic complications of CKD-MBD. The increasing evidence that the consequences of abnormal mineral metabolism are not restricted to bone disease changed the approach to the pathophysiology and treat - ment of disturbed bone and mineral metabolism in CKD patients. FGF-23 has been proposed to be the initial adap - tive response in early CKD to protect the organism from the adverse effects of phosphate retention. Increased levels of FGF-23 observed in CKD patients are associated with cardiovascular mortality risk and was shown to me - diate direct, �off-target� toxicity to the heart. This report aims to review the relevant aspects of the physiology of FGF-23 in bone biology and mineral homeostasis and the role of FGF-23 in the pathophysiology of CKD-BMD and its clinical implications.
